● Recruiting

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Condition: Familial Hypercholesterolemia - Homozygous · Sponsor: Novartis Pharmaceuticals

PhasePhase 3

Planned participants9

Who can joinAll sexes, 2 Years to 11 Years

Healthy volunteersNo

About this study

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111

Always discuss trial participation with your own doctor first.

Locations (19)

UC San Francisco Medical Center	San Francisco, California, United States	Recruiting
Childrens National Hospital	Washington D.C., District of Columbia, United States	Recruiting
Washington Univ School Of Medicine	St Louis, Missouri, United States	Recruiting
Primary Childrens Medical Center	Salt Lake City, Utah, United States	Recruiting
Novartis Investigative Site	Vienna, Austria	Recruiting
Novartis Investigative Site	Beijing, Beijing Municipality, China	Recruiting
Novartis Investigative Site	Frankfurt am Main, Hesse, Germany	Recruiting
Novartis Investigative Site	Ioannina, Greece	Recruiting
Novartis Investigative Site	Thessaloniki, Greece	Recruiting
Novartis Investigative Site	Kota Bharu, Kelantan, Malaysia	Recruiting
Novartis Investigative Site	Amsterdam, North Holland, Netherlands	Recruiting
Novartis Investigative Site	Bloemfontein, Free State, South Africa	Recruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06597006